KBI Biopharma's PUREplatform™ includes
An exceptionally clean and highly-efficient, proprietary E. coli producer cell line
A New Host Strain-Plasmid Combination
A New Core of CLD and Microbial Optimization
At KBI Biopharma, our PUREcoli cell line is our proprietary, high-producing E. Coli cell line. As part of the KBI PUREplatform, PUREcoli can be expertly paired with PUREplasmids™ and PUREmedia™ and our cutting-edge fermentation process that fits together into a complete service package, catered to your needs.
E. Coli has long been implemented as a therapeutic protein factory due to its simplicity, tractability, and wealth of information characterizing the microbe. Recent advancements in genetic engineering, analytics, and strain screening now allow for the reimagining of E. Coli as an optimal protein factory - not just a common one or as an expression system artifact.
While common E. Coli expression strains alter as many as five genes to improve one aspect of recombinant protein expression, KBI has created a platform E. Coli with ~1,000 genes altered and roughly 1 Mbp of DNA removed. Every idea aimed at optimizing the safety, identity, strength, purity, and quality (SISPQ) of recombinant proteins has been rolled into an optimal genotype associated with reduced translational and post-translational modifications, excess genes, virulent genes, ad destabilizing genes, all layered on top of an improved metabolism. The result is a PURE, efficient platform expression strain: PUREcoli.
Just one way KBI is Doing More with Microbes.
Our proprietary PUREcoli grows nearly 50% faster in fully defined media and to around 2X the cell density (up to 40% WCW) as compared to common E. Coli strains. The faster growth reduces fermentation times and the 2X higher cell density allows for 2X the potential titer. At the same time, the PUREcoli genotype is associated with higher stability and yields robust, stable protein expression. This, in combination with higher cell density, allows for exceptionally high potential titers, even for recalcitrant proteins.
Explore More Microbial:
Introducing KBI's PUREplatform™
For Clean, Efficient Therapeutic Protein Production
Pushing the Boundaries of E. Coli Expression
Within a New Standard of Premium Microbial Cell Line Development
Navigating a New Standard in Microbial Protein Expression
At KBI Biopharma, our PUREplatform™ is everything you need to make a protein. Catered to your needs, our service package contains plasmids, strains, media, and a fermentation process that fit perfectly and efficiently together. Learn more about how to easily jump-start your microbial program to reduce impurities and reach higher titers.
An ideal therapeutic protein “factory” creates a pure target product with high titers from the start, which can minimize development risk, timelines, and cost. E. coli has long been implemented as a therapeutic protein factory due to its simplicity, tractability, and wealth of information characterizing the microbe.
While common E. coli expression strains alter as many as five genes to improve one aspect of recombinant protein expression, KBI has created a platform E. coli with about 1,000 genes altered and roughly 1 Mbp of DNA removed. The result is a PURE, efficient platform expression strain—PUREcoli™.
PURE in. PURE out.
Download the Whitepaper:
Explore More Microbial Services & Capabilities:
Never Miss Another Update!
Subscribe to KBI's Newsletter, The Pulse, to stay up-to-date on all the latest news, articles, and events from KBI Biopharma.